ArticleCancer management and research2026
PET-MR Examination in Diagnosing Bone Metastases in Prostate Cancer.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Positron Emission Tomography-magnetic resonance (PET-MR) has the advantage of high contrast and has a high potential for diagnosing bone metastases in prostate cancer (PC). This study assesses the effectiveness of PET-MR imaging for detecting bone metastasis in PC. Methods: A total of 212 prostate cancer patients admitted to our hospital from June 2021 to June 2024 were selected, all of whom were diagnosed with prostate cancer through pathological puncture. According to the most valuable comparative method (BVC), patients were divided into a bone metastasis group (n=40) and a non-bone metastasis group (n=172). General information such as age was collected and compared between the two groups of patients. PET-MR examination was performed on all patients, and the number of lesions was recorded (a total of 95 bone metastases were detected). Among them, BVC confirmed 58 metastatic lesions (due to the presence of multiple site metastases in some patients). The Gleason score, SUV Results: Among patients with bone metastases, 38 patients with positive PET-MR (95.00%) and 169 patients with non-bone metastases (79.72%) were PET-MR negative. The sensitivity of PET-MR in diagnosing prostate cancer bone metastasis was 95.00% (95% CI: 83.5% - 99.4%), the specificity was 79.72% (95% CI: 73.1% - 85.3%), the positive predictive value was 92.68% (95% CI: 80.1% - 98.4%), and the negative predictive value was 98.83% (95% CI: 95.8% - 99.9%). The proportion of PET-MR diagnosed prostate cancer bone metastases with pelvic, spinal, extremity, rib, and scapular lesions were 31.03%, 44.83%, 8.62%, 3.45%, and 87.93%, respectively. Compared with the non-metastatic group, the proportion of patients with Gleason score > 9, the proportion of tPSA > 100 ng/mL, ALP level and SUV Conclusion: SUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.